» Articles » PMID: 30961450

Non-Prescribed Buprenorphine Use Mediates the Relationship Between Heroin Use and Kratom Use Among a Sample of Polysubstance Users

Overview
Specialties Pharmacology
Psychiatry
Date 2019 Apr 10
PMID 30961450
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

In Asia, (e.g., "kratom") has been used to mitigate alcohol and drug dependence. Some preliminary findings suggest kratom's potential use as an informal harm-reduction method in the United States, such as an opioid substitute or as a means of lessening opioid withdrawal symptoms. To determine correlates of past-year kratom use among a sample of polysubstance users enrolled in residential recovery programs in Kentucky, an anonymous survey was completed by clients in April 2017. Logistic regression was used to identify significant associations with past-year kratom use. Of the final sample ( = 478), 10.4% reported past-year kratom use. Past-year heroin use, but not past-year prescription opioid (e.g., oxycodone, hydrocodone) use, was significantly associated with kratom use, such that individuals who reported past-year heroin use were 2.5 times more likely to also report past-year kratom use. Non-prescribed buprenorphine (i.e., Suboxone) use partially mediated the relationship between past-year heroin and kratom use by explaining 36% of the association between the two drugs. Though amphetamines were highly preferred, past-year use was negatively correlated with past-year kratom use. Rates of past-year kratom use were lower than rates of alcohol and illicit drug use. Kratom was not preferred over heroin or prescription opioids.

Citing Articles

Scope of, Motivations for, and Outcomes Associated with Buprenorphine Diversion in the United States: A Scoping Review.

Rubel S, Eisenstat M, Wolff J, Calevski M, Mital S Subst Use Misuse. 2023; 58(5):685-697.

PMID: 36803159 PMC: 10961708. DOI: 10.1080/10826084.2023.2177972.


For Better or Worse: Self-reported Changes in Kratom and Other Substance Use as a Result of the COVID-19 Pandemic.

Rogers J, Smith K, Schriefer D, Epstein D Subst Abuse. 2022; 16:11782218221123977.

PMID: 36199697 PMC: 9527987. DOI: 10.1177/11782218221123977.


Associations of Lifetime Nonmedical Opioid, Methamphetamine, and Kratom Use within a Nationally Representative US Sample.

Smith K, Rogers J, Strickland J J Psychoactive Drugs. 2021; 54(5):429-439.

PMID: 34842079 PMC: 9148372. DOI: 10.1080/02791072.2021.2006374.


Social, psychological, and substance use characteristics of U.S. adults who use kratom: Initial findings from an online, crowdsourced study.

Smith K, Dunn K, Grundmann O, Garcia-Romeu A, Rogers J, Swogger M Exp Clin Psychopharmacol. 2021; 30(6):983-996.

PMID: 34735202 PMC: 10726725. DOI: 10.1037/pha0000518.


Characterization of diverted buprenorphine use among adults entering corrections-based drug treatment in Kentucky.

Smith K, Tillson M, Staton M, Winston E Drug Alcohol Depend. 2020; 208:107837.

PMID: 31951906 PMC: 7418075. DOI: 10.1016/j.drugalcdep.2020.107837.

References
1.
Moody L, Satterwhite E, Bickel W . Substance Use in Rural Central Appalachia: Current Status and Treatment Considerations. Rural Ment Health. 2017; 41(2):123-135. PMC: 5648074. DOI: 10.1037/rmh0000064. View

2.
Lin H, Wang Z, Boyd C, Simoni-Wastila L, Buu A . Associations between statewide prescription drug monitoring program (PDMP) requirement and physician patterns of prescribing opioid analgesics for patients with non-cancer chronic pain. Addict Behav. 2017; 76:348-354. DOI: 10.1016/j.addbeh.2017.08.032. View

3.
Daniulaityte R, Falck R, Carlson R . Illicit use of buprenorphine in a community sample of young adult non-medical users of pharmaceutical opioids. Drug Alcohol Depend. 2011; 122(3):201-7. PMC: 3293107. DOI: 10.1016/j.drugalcdep.2011.09.029. View

4.
Singh D, Narayanan S, Muller C, Swogger M, Rahim A, Leong Bin Abdullah M . Severity of Kratom (Mitragyna speciosa Korth.) Psychological Withdrawal Symptoms. J Psychoactive Drugs. 2018; 50(5):445-450. DOI: 10.1080/02791072.2018.1511879. View

5.
Saingam D, Assanangkornchai S, Geater A, Lerkiatbundit S . Factor Analytical Investigation of Krathom (Mitragyna speciosa Korth.) Withdrawal Syndrome in Thailand. J Psychoactive Drugs. 2016; 48(2):76-85. DOI: 10.1080/02791072.2016.1156791. View